Alfuzosin

CHEMBL709 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

389.4 g/mol

LogP

1.7

Phase

4

An alpha-1 adrenergic blocker that relaxes the muscles of the prostate and bladder neck, making it easier to urinate in men with benign prostatic hyperplasia (BPH). It improves urinary flow and reduces symptoms such as incomplete bladder emptying, frequent urination, and nighttime awakenings to urinate.

Masse moléculaire

389,4000 g/mol

LogP

1,70

TPSA

112,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Benign Prostatic Hyperplasia Cardiovascular Disease Respiratory Disease Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC

InChI

InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)

Molecular Formula

C19H27N5O4

HBD / HBA

2 / 8

Liaisons Rotatives

8

Atomes Lourds

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An alpha-1 adrenergic blocker that relaxes the muscles of the prostate and bladder neck, making it easier to urinate in men with benign prostatic hyperplasia (BPH). It improves urinary flow and reduces symptoms such as incomplete bladder emptying, frequent urination, and nighttime awakenings to urinate.

Yes, Alfuzosin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL709. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2092. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Alfuzosin sur PillFYI

Structure

Données Clés

Formule: C19H27N5O4
Synonymes: 3

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.